http://www.acc.org/Feed?clinicalTopicID=9445effd-ba3f-4faa-8061-b82d69552947 Clinical Topic Feed: Interventions and ACS en /Latest-in-Cardiology/Articles/2026/04/07/19/53/host-exam-acc-2026 Clopidogrel monotherapy after PCI was associated with a significantly lower composite risk of all-cause death, nonfatal MI, stroke, readmission for acute coronary syndrome (ACS) and major bleeding compared with aspirin monotherapy, according to 10-year follow-up results of the HOST-EXAM trial presented as featured clinical research at ACC.26 and published simultaneously in The Lancet. 1775593440000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-830am-fastIII-acc-2026 Vessel fractional flow reserve (vFFR)-guided revascularization was noninferior to pressure-wire-based fractional flow reserve (FFR)-guided revascularization in patients with intermediate coronary lesions, according to results from the FAST III trial presented during a Late-Breaking Clinical Trials session... 1774791180000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/18/00/50/eagles-eye-view-18mar2025 In this week’s View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. 1773842400000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/10/16/54/RENOVATE-COMPLEX-PCI-Benefit-With-Intravascular In the multicenter open-label superiority trial, Joo Myung Lee, MD, MPH, PhD, FACC, et al., randomized 1,639 patients (mean age 66; 20% women) with complex coronary artery lesions across 20 hospitals in South Korea 2:1 to either intravascular imaging-guided PCI (n=1,092) or angiography-guided PCI (n=547). Of the overall cohort, 49% presented with stable ischemic heart disease and 51% with an acute coronary syndrome (ACS). Thirty-one percent had three or more characteristics of complex coronary artery lesions in the target lesion. The most common was long coronary lesion, followed by multivessel PCI, true bifurcation lesion and chronic total occlusion. 1773162180000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/04/14/11/eagles-eye-view-04mar2025 In this week’s View, Dr. Eagle looks at increased one-year mortality in younger patients undergoing transcatheter aortic valve replacement (TAVR). 1772636400000 Articles and Stories /Latest-in-Cardiology/Articles/2025/12/08/18/14/Demystifying-Antiplatelet-Therapy The optimal management of dual antiplatelet therapy (DAPT) in patients presenting with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) remains a dynamic and evolving area. 1765224600000 Articles and Stories /Latest-in-Cardiology/Articles/2025/12/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1764594300000 Articles and Stories /Latest-in-Cardiology/Articles/2025/12/01/01/Journal-Wrap The hottest research from various peer-reviewed journals – handpicked weekly by the ACC. 1764594240000 Articles and Stories /Latest-in-Cardiology/Clinical-Trials/2025/12/17/18/59/CELEBRATE The CELEBRATE trial demonstrated that a single injection of zalunfiban administered at first medical contact in patients with suspected STEMI significantly improved patency of the infarct-related artery at index angiography and reduced the likelihood of a composite of all-cause death, stroke, recurrent myocardial infarction (MI), stent thrombosis, heart failure, and larger MI at 30 days. 1762801200000 Articles and Stories /Latest-in-Cardiology/Articles/2025/11/03/16/19/mon-915am-tuxedo-aha-2025 In patients with diabetes and multivessel coronary artery disease undergoing PCI, a ticagrelor-based dual antiplatelet therapy (DAPT) regimen did not offer the same level of benefit at preventing heart attack, stroke, bleeding complications or death as a prasugrel-based DAPT regimen... 1762784100000 Articles and Stories